A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).
Carey K. Anders(Duke University), Sara M. Tolaney(Harvard University), Denise A. Yardley(Sarah Cannon), PierFranco Conte(University of Padua), Thomas Bachelot(Centre Léon Bérard), Yanyun Chen(Eli Lilly (United States)), Zhengyu Yang(Monash University), Émilie Le Rhun(University of Zurich), Ahmad Awada(Centre Hospitalier Interrégional Edith Cavell), Melissa Bear(Eli Lilly (United States)), Peter Kabos(University of Colorado Anschutz Medical Campus)
Cited by 39
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k